FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
The FDA approved the first medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Alcoholism | Diets | Drugs & Pharmacology | Fatty Liver Disease (FLD) | Liver | Liver Disease | Nutrition | Sports Medicine | Urology & Nephrology